Cyclacel Pharmaceuticals, Inc.
NASDAQ: CYCC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sing Ee Wong
- Employees
- 12
- Headquarters
- Berkeley Heights, United States
- IPO year
- 2004
- Market cap
- $10.6M
- Website
- https://www.cyclacel.com
Loading CYCC…
Loading profile data…Frequently asked questions about CYCC
What does Cyclacel Pharmaceuticals, Inc. (CYCC) do?
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhib...
Where does CYCC trade?
Cyclacel Pharmaceuticals, Inc. (CYCC) trades on the NASDAQ Capital Market.
What sector is CYCC in?
Cyclacel Pharmaceuticals, Inc. (CYCC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cyclacel Pharmaceuticals, Inc.?
Sing Ee Wong is the chief executive officer of Cyclacel Pharmaceuticals, Inc. (CYCC).
Where is Cyclacel Pharmaceuticals, Inc. headquartered?
Cyclacel Pharmaceuticals, Inc. is headquartered in United States.
Does CYCC pay a dividend?
Yes — Cyclacel Pharmaceuticals, Inc. (CYCC) paid a trailing twelve-month dividend of USD 0.15 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did CYCC go public?
Cyclacel Pharmaceuticals, Inc. (CYCC) completed its initial public offering in 2004.